Major bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · people with ST of the leg
Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux leads to higher major bleeding compared with LMWH (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes major bleeding compared with variable dose warfarin (very low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes major bleeding compared with 1 mg warfarin (very low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
Major bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in major Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review